Smithfield Trust Co Cuts Stock Position in Pfizer Inc. $PFE

Smithfield Trust Co trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 11.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 62,358 shares of the biopharmaceutical company’s stock after selling 8,132 shares during the quarter. Smithfield Trust Co’s holdings in Pfizer were worth $1,511,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of PFE. Vanguard Group Inc. boosted its stake in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares during the last quarter. Northern Trust Corp boosted its position in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. Amundi grew its stake in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Finally, Invesco Ltd. increased its position in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after buying an additional 838,198 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

Shares of PFE opened at $25.84 on Thursday. The business’s 50-day moving average is $24.77 and its two-hundred day moving average is $24.42. The company has a market capitalization of $146.92 billion, a P/E ratio of 13.75, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 100.00%.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.